Literature DB >> 9846987

Loss of heterozygosity and microsatellite instability in de novo versus ex-adenoma carcinomas of the colorectum.

J D Mueller1, N Haegle, G Keller, E Mueller, G Saretzky, B Bethke, M Stolte, H Höfler.   

Abstract

Small adenocarcinomas of the colorectum showing no evidence of origin from an adenoma have been called de novo carcinomas, a name that implies an origin via a different molecular genetic mechanism than the usual colorectal carcinoma which develops from an adenoma. Using microsatellite analysis, 35 early (pT1) de novo and 36 pT1 ex-adenoma carcinomas were compared using 8 microsatellite loci at 6 different chromosomal loci (1p, 2p, 8p, 5q, 17p, and 18q) known or hypothesized to be important for colorectal carcinogenesis. The rate of loss of heterozygosity (LOH) at the 17p locus (near the p53 gene) was significantly higher in the de novo than in the ex-adenoma group (73 vs. 37%, P = 0.004). The rates of LOH at the other loci (including the APC and DCC genes) and the rate of MSI were not significantly different in the two groups. These results indicate that de novo carcinomas of the colorectum develop via a similar carcinogenetic pathway as conventional ex-adenoma carcinomas; however, their higher rate of LOH at 17p is evidence for a biologically more advanced lesion with more frequent p53 mutations, consistent with clinicopathological data indicating that de novo carcinomas are more aggressive than ex-adenoma carcinomas.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9846987      PMCID: PMC1866329          DOI: 10.1016/S0002-9440(10)65711-2

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  27 in total

1.  Genetic alterations during colorectal-tumor development.

Authors:  B Vogelstein; E R Fearon; S R Hamilton; S E Kern; A C Preisinger; M Leppert; Y Nakamura; R White; A M Smits; J L Bos
Journal:  N Engl J Med       Date:  1988-09-01       Impact factor: 91.245

2.  Growth patterns and prognosis in early gastric carcinoma. Superficially spreading and penetrating growth types.

Authors:  Y Kodama; K Inokuchi; K Soejima; T Matsusaka; T Okamura
Journal:  Cancer       Date:  1983-01-15       Impact factor: 6.860

3.  APC and p53 mutations in de novo colorectal adenocarcinomas.

Authors:  T Aoki; S Takeda; A Yanagisawa; Y Kato; Y Ajioka; H Watanabe; S Kudo; Y Nakamura
Journal:  Hum Mutat       Date:  1994       Impact factor: 4.878

4.  Evidence for the presence of two tumor suppressor genes on chromosome 8p for colorectal carcinoma.

Authors:  Y Fujiwara; M Emi; H Ohata; Y Kato; T Nakajima; T Mori; Y Nakamura
Journal:  Cancer Res       Date:  1993-03-01       Impact factor: 12.701

5.  Non-involvement of ras mutations in flat colorectal adenomas and carcinomas.

Authors:  T Fujimori; K Satonaka; Y Yamamura-Idei; K Nagasako; S Maeda
Journal:  Int J Cancer       Date:  1994-04-01       Impact factor: 7.396

Review 6.  Suppressor gene alterations in the colorectal adenoma-carcinoma sequence.

Authors:  K R Cho; B Vogelstein
Journal:  J Cell Biochem Suppl       Date:  1992

7.  Adenoma--carcinoma sequence or "de novo" carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers.

Authors:  L Bedenne; J Faivre; M C Boutron; F Piard; J M Cauvin; P Hillon
Journal:  Cancer       Date:  1992-02-15       Impact factor: 6.860

8.  Early colorectal carcinoma with special reference to its development de novo.

Authors:  T Shimoda; M Ikegami; J Fujisaki; T Matsui; S Aizawa; E Ishikawa
Journal:  Cancer       Date:  1989-09-01       Impact factor: 6.860

Review 9.  Genetic alterations in the adenoma--carcinoma sequence.

Authors:  K R Cho; B Vogelstein
Journal:  Cancer       Date:  1992-09-15       Impact factor: 6.860

10.  Molecular genetics for clinical management of colorectal carcinoma. 17p, 18q, and 22q loss of heterozygosity and decreased DCC expression are correlated with the metastatic potential.

Authors:  H Iino; M Fukayama; Y Maeda; M Koike; T Mori; T Takahashi; R Kikuchi-Yanoshita; M Miyaki; S Mizuno; S Watanabe
Journal:  Cancer       Date:  1994-03-01       Impact factor: 6.860

View more
  6 in total

1.  [Differential diagnostics of hereditary colorectal cancer syndromes. The role of pathology].

Authors:  J Rüschoff; E Heinmöller; A Hartmann; R Büttner; T Rau
Journal:  Pathologe       Date:  2010-10       Impact factor: 1.011

2.  Prognostic values of chromosome 18q microsatellite alterations in stage II colonic carcinoma.

Authors:  Wei Wang; Guo-Qiang Wang; Xiao-Wei Sun; Gong Chen; Yuan-Fang Li; Li-Yi Zhang; Hai-Bo Qiu; Chun-Yu Huang; You-Qing Zhan; Zhi-Wei Zhou
Journal:  World J Gastroenterol       Date:  2010-12-21       Impact factor: 5.742

3.  Distinct molecular patterns based on proximal and distal sporadic colorectal cancer: arguments for different mechanisms in the tumorigenesis.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Nicoletta Campanini; Gabriella Di Cola; Giovanni Bader; Antonio Mazzeo; Carlo Salvemini; Silvia Morari; Davide Di Mauro; Enrico Donadei; Luigi Roncoroni; Cesare Bordi; Leopoldo Sarli
Journal:  Int J Colorectal Dis       Date:  2006-09-21       Impact factor: 2.571

4.  Sporadic colorectal carcinomas with low-level microsatellite instability: a distinct subgroup with specific clinicopathological and molecular features.

Authors:  Cinzia Azzoni; Lorena Bottarelli; Stefano Cecchini; Enrico Maria Silini; Cesare Bordi; Leopoldo Sarli
Journal:  Int J Colorectal Dis       Date:  2011-02-19       Impact factor: 2.571

5.  Selective loss of codon 72 proline p53 and frequent mutational inactivation of the retained arginine allele in colorectal cancer.

Authors:  Regine Schneider-Stock; Carsten Boltze; Brigitte Peters; Reinhard Szibor; Olfert Landt; Frank Meyer; Albert Roessner
Journal:  Neoplasia       Date:  2004 Sep-Oct       Impact factor: 5.715

6.  Gene expression profiling of colorectal adenomas and early invasive carcinomas by cDNA array analysis.

Authors:  K Nosho; H Yamamoto; Y Adachi; T Endo; Y Hinoda; K Imai
Journal:  Br J Cancer       Date:  2005-04-11       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.